400 related articles for article (PubMed ID: 28476636)
1. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
[TBL] [Abstract][Full Text] [Related]
2. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
[TBL] [Abstract][Full Text] [Related]
3. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
[TBL] [Abstract][Full Text] [Related]
4. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.
Bae EJ; Lee HJ; Rockenstein E; Ho DH; Park EB; Yang NY; Desplats P; Masliah E; Lee SJ
J Neurosci; 2012 Sep; 32(39):13454-69. PubMed ID: 23015436
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
[TBL] [Abstract][Full Text] [Related]
6. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
9. Transmission of Soluble and Insoluble α-Synuclein to Mice.
Jones DR; Delenclos M; Baine AT; DeTure M; Murray ME; Dickson DW; McLean PJ
J Neuropathol Exp Neurol; 2015 Dec; 74(12):1158-69. PubMed ID: 26574670
[TBL] [Abstract][Full Text] [Related]
10. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
Paleologou KE; Kragh CL; Mann DM; Salem SA; Al-Shami R; Allsop D; Hassan AH; Jensen PH; El-Agnaf OM
Brain; 2009 Apr; 132(Pt 4):1093-101. PubMed ID: 19155272
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
[TBL] [Abstract][Full Text] [Related]
12. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
Masliah E; Rockenstein E; Mante M; Crews L; Spencer B; Adame A; Patrick C; Trejo M; Ubhi K; Rohn TT; Mueller-Steiner S; Seubert P; Barbour R; McConlogue L; Buttini M; Games D; Schenk D
PLoS One; 2011 Apr; 6(4):e19338. PubMed ID: 21559417
[TBL] [Abstract][Full Text] [Related]
13. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
Masliah E; Rockenstein E; Adame A; Alford M; Crews L; Hashimoto M; Seubert P; Lee M; Goldstein J; Chilcote T; Games D; Schenk D
Neuron; 2005 Jun; 46(6):857-68. PubMed ID: 15953415
[TBL] [Abstract][Full Text] [Related]
14. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
[TBL] [Abstract][Full Text] [Related]
15. Solubility of α-synuclein species in the L62 mouse model of synucleinopathy.
Schwab K; Magbagbeolu M; Theuring F; Harrington CR; Wischik CM; Riedel G
Sci Rep; 2024 Mar; 14(1):6239. PubMed ID: 38486089
[TBL] [Abstract][Full Text] [Related]
16. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
17. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
Mandler M; Valera E; Rockenstein E; Mante M; Weninger H; Patrick C; Adame A; Schmidhuber S; Santic R; Schneeberger A; Schmidt W; Mattner F; Masliah E
Mol Neurodegener; 2015 Mar; 10():10. PubMed ID: 25886309
[TBL] [Abstract][Full Text] [Related]
18. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods.
Tarutani A; Arai T; Murayama S; Hisanaga SI; Hasegawa M
Acta Neuropathol Commun; 2018 Apr; 6(1):29. PubMed ID: 29669601
[TBL] [Abstract][Full Text] [Related]
19. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
[TBL] [Abstract][Full Text] [Related]
20. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
Mandler M; Valera E; Rockenstein E; Weninger H; Patrick C; Adame A; Santic R; Meindl S; Vigl B; Smrzka O; Schneeberger A; Mattner F; Masliah E
Acta Neuropathol; 2014; 127(6):861-79. PubMed ID: 24525765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
